947P First-in-class CBL-B inhibitor NX-1607: Phase Ia data in patients with advanced solid tumors
2025 · Annals of Oncology · 0 citations
https://doi.org/10.1016/j.annonc.2025.08.1516
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
5
Papers
7
Citations
1
h-index
0
i10-index
A. Williams is an academic researcher from Sarah Cannon Research Institute. The author has contributed to research in topics: BRCA gene mutations in cancer & PARP inhibition in cancer therapy & Advanced Breast Cancer Therapies. The author has an h-index of 1, co-authored 5 publications.
ORCID: 0000-0002-9542-1769Click to start Chat